Study Shows Effectiveness of Merakris’ Wound Care Products RESEARCH TRIANGLE PARK, N.C., June 02, 2022 (GLOBE NEWSWIRE) -- A peer-reviewed case study in the May 21 edition of SAGE Open Medical Case Reports highlights the effectiveness of two Merakris...

Study in Modern Optometry Shows Effectiveness Of Merakris Therapeutics’ Eye Product, Opticyte® Matrix RESEARCH TRIANGLE PARK, N.C., March 24, 2022 (GLOBE NEWSWIRE) -- Opticyte® Amniotic Ocular Matrix, a product of Research Triangle Park-based Merakris Therapeutics, has gotten the attention of a...

Merakris and Dept. of Veterans Affairs Sign CRADA Agreement – Clinical Trial for Dermacyte® Wound Care Product To Begin Soon RESEARCH TRIANGLE PARK, N.C., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Merakris Therapeutics announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United...

Merakris Announces Agreement With Miracles In Sight Eye Bank To Supply Opticyte® Repair Grafts to Eye Surgeons RESEARCH TRIANGLE PARK, N.C., July 20, 2021 (GLOBE NEWSWIRE) -- Research Triangle Park-based biotechnology company Merakris Therapeutics has reached an agreement with Miracles In Sight (MIS) to...

Merakris Therapeutics, Inc. Announces FDA Clearance for Dermacyte® Liquid Clinical Trial RESEARCH TRIANGLE PARK, N.C., May 25, 2021 (GLOBE NEWSWIRE) -- Merakris Therapeutics, Inc. (Merakris) announced that it has received U.S. Food and Drug Administration (FDA) clearance for a Phase II...